FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:763-764 August 14, 2008 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kerbel, R. S. PubMed Citation

To the Editor: In the review of tumor angiogenesis by Kerbel (May 8 issue),¹ endothelial progenitors are described as negative for CD45, positive for vascular endothelial growth factor receptor 2 (VEGFR-2), and positive for CD133, and the review by Bertolini et al.² is cited as the source for this definition. This assertion is incorrect; in the article by Bertolini et al., endothelial progenitors are actually defined as CD45dimCD34+VEGFR-2+CD133+ cells.

Flow cytometric analyses that we performed on blood from normal subjects showed that, among CD34+ cells, a discrete population of CD45dimCD133+VEGFR-2+ cells could be discerned. Back-gating on VEGFR-2+CD133+ cells showed that . . . [Full Text of this Article]

This article has been cited by other articles:

• Taylor, M., Rossler, J., Geoerger, B., Laplanche, A., Hartmann, O., Vassal, G., Farace, F. (2009). High Levels of Circulating VEGFR2+ Bone Marrow-Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies. Clin. Cancer Res. 15: 4561-4571 [Abstract] [Full Text]